RANDOMIZED DOUBLE-BLIND-STUDY OF NABUMETONE AND PIROXICAM IN THE TREATMENT OF OSTEOARTHRITIS IN DUTCH GENERAL-PRACTICE - EFFICACY AND TOLERABILITY

被引:0
作者
DEBOCK, GH [1 ]
HERMANS, J [1 ]
MULDER, JD [1 ]
机构
[1] LEIDEN UNIV,DEPT MED STAT,2300 RA LEIDEN,NETHERLANDS
来源
PHARMACY WORLD & SCIENCE | 1993年 / 15卷 / 03期
关键词
FAMILY PRACTICE; NABUMETONE; OSTEOARTHRITIS; PIROXICAM; RANDOMIZED CONTROLLED TRIALS; SIDE EFFECTS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To study nabumetone (1,000 mg once daily) by comparison with piroxicam (20 mg once daily) in patients with osteoarthritis, a randomized, double-blind trail was set up in 40 general practices. Evaluation was based on clinical outcome in 198 patients. There was some evidence that nabumetone is associated with a lower and less severe occurrence of gastric pain, and with more withdrawals due to lack of efficacy. Although the differences between nabumetone and piroxicam were small in this study, these were clinically relevant. The general practitioner should balance the respective benefits of greater safety and tolerance against greater efficacy in meeting the requirements of an individual patient with osteoarthritis.
引用
收藏
页码:132 / 138
页数:7
相关论文
共 50 条
[21]   Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis:: randomized, placebo-controlled, double blind clinical trial [J].
Schmid, B ;
Lüdtke, R ;
Selbmann, HK ;
Kötter, I ;
Tschirdewahn, B ;
Schaffner, W ;
Heide, L .
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2000, 59 (05) :314-320
[22]   Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis:: Randomized placebo-controlled, double blind clinical trial [J].
Schmid, B ;
Lüdtke, R ;
Selbmann, HK ;
Kötter, I ;
Tschirdewahn, B ;
Schaffner, W ;
Heide, L .
PHYTOTHERAPY RESEARCH, 2001, 15 (04) :344-350
[23]   Comparative Clinical Trial of S-Adenosylmethionine Versus Nabumetone for the Treatment of Knee Osteoarthritis: An 8-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Phase IV Study in Korean Patients [J].
Kim, Jinhyun ;
Lee, Eun Young ;
Koh, Eun-Mi ;
Cha, Hoon-Suk ;
Yoo, Bin ;
Lee, Chang Keun ;
Lee, Yunjong ;
Ryu, Heejung ;
Lee, Ki Hoon ;
Song, Yeong Wook .
CLINICAL THERAPEUTICS, 2009, 31 (12) :2860-2872
[24]   Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study [J].
Lugo, James P. ;
Saiyed, Zainulabedin M. ;
Lane, Nancy E. .
NUTRITION JOURNAL, 2016, 15
[25]   Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study [J].
James P. Lugo ;
Zainulabedin M. Saiyed ;
Nancy E. Lane .
Nutrition Journal, 15
[26]   Efficacy of intra-articular polynucleotides in the treatment of knee osteoarthritis: a randomized, double-blind clinical trial [J].
Roberto Vanelli ;
Pietro Costa ;
Stefano Marco Paolo Rossi ;
Francesco Benazzo .
Knee Surgery, Sports Traumatology, Arthroscopy, 2010, 18 :901-907
[27]   Efficacy of intra-articular polynucleotides in the treatment of knee osteoarthritis: a randomized, double-blind clinical trial [J].
Vanelli, Roberto ;
Costa, Pietro ;
Rossi, Stefano Marco Paolo ;
Benazzo, Francesco .
KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY, 2010, 18 (07) :901-907
[28]   Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial [J].
Leung, AT ;
Malmstrom, K ;
Gallacher, AE ;
Sarembock, B ;
Poor, G ;
Beaulieu, A ;
Castro, R ;
Sanchez, M ;
DeTora, LM ;
Ng, J .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (02) :49-58
[29]   DOUBLE-BLIND-STUDY ON THE EFFICACY OF ETODOLAC VERSUS PIROXIC AM IN THE TREATMENT OF ACUTE LOW-BACK-PAIN [J].
ARRIAGADA, M ;
ARINOVICHE, R .
REVISTA MEDICA DE CHILE, 1992, 120 (01) :54-58
[30]   Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib [J].
Lehmann, R ;
Brzosko, M ;
Kopsa, P ;
Nischik, R ;
Kreiss, A ;
Thurston, H ;
Litschig, S ;
Sloan, VS .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (04) :517-526